Although the molecular mechanisms of EMP affecting the various steps of the cancer-immunity cycle are still largely obscure, targeting EMP represents a promising therapeutic addition within the overarching strategy of personalized cancer immunotherapy to re-activate a halting cancer-immunity cycle and re-establish a robust host immune response against the cancer cells[53,121]. Here, MAEA is linked to cancer.